Gelesis rounds up $3.6M in fresh venture funds

Gelesis, a biotech startup focused on developing new obesity treatments, has raised $3.6 million, reports Globes. The new money brings its total take to date to $20 million. Gelesis was one of FierceBiotech's Fierce 15 in 2010. Story

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.